{"id":2398,"date":"2026-07-20T11:35:05","date_gmt":"2026-07-20T08:35:05","guid":{"rendered":"https:\/\/demetdemircioglu.com\/?p=2398"},"modified":"2026-07-20T11:47:54","modified_gmt":"2026-07-20T08:47:54","slug":"prp-kikirdagi-yeniler-mi","status":"publish","type":"post","link":"https:\/\/demetdemircioglu.com\/en\/prp-kikirdagi-yeniler-mi\/","title":{"rendered":"PRP K\u0131k\u0131rda\u011f\u0131 Yeniler mi? Diz Kire\u00e7lenmesinde Bilimsel Kan\u0131tlar Ne S\u00f6yl\u00fcyor?"},"content":{"rendered":"<p class=\"gtfy-1 wp-block-paragraph\"><strong>PRP k\u0131k\u0131rda\u011f\u0131 ger\u00e7ekten yeniler mi?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-4 wp-block-paragraph\">Diz kire\u00e7lenmesi nedeniyle PRP tedavisi d\u00fc\u015f\u00fcnen hastalar\u0131n en s\u0131k sordu\u011fu sorulardan biri \u015fudur:<\/p>\n\n\n\n<p class=\"gtfy-7 wp-block-paragraph\"><strong>\u201cPRP yapt\u0131r\u0131rsam dizimdeki k\u0131k\u0131rdak yeniden olu\u015fur mu?\u201d<\/strong><\/p>\n\n\n\n<p class=\"gtfy-10 wp-block-paragraph\">G\u00fcncel bilimsel veriler \u0131\u015f\u0131\u011f\u0131nda bu sorunun en do\u011fru cevab\u0131 \u015f\u00f6yledir:<\/p>\n\n\n\n<p class=\"gtfy-13 wp-block-paragraph\">PRP, uygun se\u00e7ilmi\u015f baz\u0131 hastalarda a\u011fr\u0131y\u0131 azaltabilir ve diz fonksiyonlar\u0131n\u0131 iyile\u015ftirebilir.<\/p>\n\n\n\n<p class=\"gtfy-16 wp-block-paragraph\">Ancak kaybedilmi\u015f eklem k\u0131k\u0131rda\u011f\u0131n\u0131 g\u00fcvenilir ve kal\u0131c\u0131 bi\u00e7imde yeniden olu\u015fturdu\u011fu hen\u00fcz kan\u0131tlanmam\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"gtfy-19 wp-block-paragraph\">Ba\u015fka bir ifadeyle, PRP sonras\u0131nda a\u011fr\u0131n\u0131n azalmas\u0131 veya y\u00fcr\u00fcmenin kolayla\u015fmas\u0131 de\u011ferli bir klinik sonu\u00e7tur;<\/p>\n\n\n\n<p class=\"gtfy-22 wp-block-paragraph\">ancak bu iyile\u015fme otomatik olarak \u201ck\u0131k\u0131rdak yeniden olu\u015ftu\u201d anlam\u0131na gelmez.<\/p>\n\n\n\n<p class=\"gtfy-25 wp-block-paragraph\"><strong>PRP nedir?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-28 wp-block-paragraph\">PRP, \u201cplatelet-rich plasma\u201d, T\u00fcrk\u00e7esiyle trombositten zengin plazma anlam\u0131na gelir. Hastan\u0131n kendi kan\u0131ndan haz\u0131rlanan bu \u00fcr\u00fcn, belirli santrif\u00fcj i\u015flemleriyle trombositlerin plazma i\u00e7erisinde yo\u011funla\u015ft\u0131r\u0131lmas\u0131yla elde edilir.<\/p>\n\n\n\n<p class=\"gtfy-31 wp-block-paragraph\">Trombositler yaln\u0131zca p\u0131ht\u0131la\u015fmada g\u00f6rev alan h\u00fccresel par\u00e7ac\u0131klar de\u011fildir. Ayn\u0131 zamanda b\u00fcy\u00fcme fakt\u00f6rleri, sitokinler ve doku iyile\u015fme s\u00fcre\u00e7lerini etkileyebilen \u00e7e\u015fitli biyolojik mediyat\u00f6rler i\u00e7erir.<\/p>\n\n\n\n<p class=\"gtfy-34 wp-block-paragraph\">PRP uygulamas\u0131n\u0131n amac\u0131, hasarl\u0131 veya dejeneratif dokunun biyolojik \u00e7evresini etkileyerek:<\/p>\n\n\n\n<p class=\"gtfy-37 wp-block-paragraph\">\u0130nflamatuvar yan\u0131t\u0131 d\u00fczenlemek,<\/p>\n\n\n\n<p class=\"gtfy-40 wp-block-paragraph\">A\u011fr\u0131yla ili\u015fkili biyolojik mekanizmalar\u0131 azaltmak,<\/p>\n\n\n\n<p class=\"gtfy-43 wp-block-paragraph\">H\u00fccreler aras\u0131 ileti\u015fimi de\u011fi\u015ftirmek,<\/p>\n\n\n\n<p class=\"gtfy-46 wp-block-paragraph\">Doku onar\u0131m\u0131na uygun bir mikro\u00e7evre olu\u015fturmak olarak \u00f6zetlenebilir.<\/p>\n\n\n\n<p class=\"gtfy-49 wp-block-paragraph\">Ancak PRP bir k\u00f6k h\u00fccre tedavisi de\u011fildir. \u0130\u00e7erisinde standartla\u015ft\u0131r\u0131lm\u0131\u015f bir k\u00f6k h\u00fccre dozu bulunmaz ve do\u011frudan yeni k\u0131k\u0131rdak h\u00fccrelerine d\u00f6n\u00fc\u015fmesi beklenmez.<\/p>\n\n\n\n<p class=\"gtfy-52 wp-block-paragraph\">A\u011fr\u0131n\u0131n azalmas\u0131 ile k\u0131k\u0131rdak yenilenmesi ayn\u0131 \u015fey de\u011fildir Bir tedavinin ba\u015far\u0131l\u0131 olup olmad\u0131\u011f\u0131n\u0131 de\u011ferlendirirken klinik ve yap\u0131sal sonu\u00e7lar\u0131 birbirinden ay\u0131rmak gerekir.<\/p>\n\n\n\n<p class=\"gtfy-55 wp-block-paragraph\"><strong>Klinik iyile\u015fme<\/strong><\/p>\n\n\n\n<p class=\"gtfy-58 wp-block-paragraph\"><strong>Klinik iyile\u015fme \u015fu sonu\u00e7lar\u0131 kapsayabilir:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-61 wp-block-paragraph\">A\u011fr\u0131n\u0131n azalmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-64 wp-block-paragraph\">Merdiven \u00e7\u0131kman\u0131n kolayla\u015fmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-67 wp-block-paragraph\">Y\u00fcr\u00fcme mesafesinin artmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-70 wp-block-paragraph\">Diz sertli\u011finin azalmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-73 wp-block-paragraph\">G\u00fcnl\u00fck ya\u015fam aktivitelerinin daha rahat yap\u0131lmas\u0131.<\/p>\n\n\n\n<p class=\"gtfy-76 wp-block-paragraph\">Yap\u0131sal iyile\u015fme<\/p>\n\n\n\n<p class=\"gtfy-79 wp-block-paragraph\"><strong>Ger\u00e7ek bir k\u0131k\u0131rdak rejenerasyonundan s\u00f6z edebilmek i\u00e7in ise daha g\u00fc\u00e7l\u00fc bulgular gerekir:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-82 wp-block-paragraph\">Kaybedilmi\u015f k\u0131k\u0131rdak hacminin artmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-85 wp-block-paragraph\">K\u0131k\u0131rdak kal\u0131nl\u0131\u011f\u0131n\u0131n y\u00fck ta\u015f\u0131yan hasarl\u0131 b\u00f6lgelerde yeniden olu\u015fmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-88 wp-block-paragraph\">Yeni dokunun normal hiyalin k\u0131k\u0131rda\u011fa benzer \u00f6zellik ta\u015f\u0131mas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-91 wp-block-paragraph\">Bu de\u011fi\u015fikli\u011fin uygun bir kontrol grubuna k\u0131yasla g\u00f6sterilmesi,<\/p>\n\n\n\n<p class=\"gtfy-94 wp-block-paragraph\">Yap\u0131sal etkinin uzun s\u00fcre korunmas\u0131.<\/p>\n\n\n\n<p class=\"gtfy-97 wp-block-paragraph\">Dolay\u0131s\u0131yla hastan\u0131n PRP sonras\u0131nda daha az a\u011fr\u0131 hissetmesi, mutlaka yeni k\u0131k\u0131rdak olu\u015ftu\u011fu anlam\u0131na gelmez.<\/p>\n\n\n\n<p class=\"gtfy-100 wp-block-paragraph\"><strong>Ara\u015ft\u0131rmalar PRP\u2019nin a\u011fr\u0131 \u00fczerindeki etkisi hakk\u0131nda ne s\u00f6yl\u00fcyor?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-103 wp-block-paragraph\">2025 y\u0131l\u0131nda yay\u0131mlanan ve 18 randomize kontroll\u00fc \u00e7al\u0131\u015fmay\u0131 kapsayan bir meta-analizde, yakla\u015f\u0131k 2.000 diz osteoartriti hastas\u0131 de\u011ferlendirildi. PRP uygulanan hastalarda plaseboya k\u0131yasla \u00f6zellikle ilk \u00fc\u00e7 ve alt\u0131 ayda<\/p>\n\n\n\n<p class=\"gtfy-106 wp-block-paragraph\">a\u011fr\u0131 azalmas\u0131, baz\u0131 fonksiyonel \u00f6l\u00e7eklerde ise 12 aya kadar uzanabilen iyile\u015fmeler bildirildi.<\/p>\n\n\n\n<p class=\"gtfy-109 wp-block-paragraph\">Bu sonu\u00e7lar, PRP\u2019nin se\u00e7ilmi\u015f hastalarda semptom kontrol\u00fcne katk\u0131da bulunabilece\u011fini g\u00f6stermektedir.<\/p>\n\n\n\n<p class=\"gtfy-112 wp-block-paragraph\">Bununla birlikte bu meta-analizdeki klinik iyile\u015fmeler, PRP\u2019nin k\u0131k\u0131rda\u011f\u0131 yeniden olu\u015fturdu\u011funu kan\u0131tlamamaktad\u0131r.<\/p>\n\n\n\n<p class=\"gtfy-115 wp-block-paragraph\">Ara\u015ft\u0131rmalar aras\u0131nda PRP\u2019nin haz\u0131rlanma y\u00f6ntemi, trombosit yo\u011funlu\u011fu, l\u00f6kosit i\u00e7eri\u011fi, aktivasyon y\u00f6ntemi ve uygulama say\u0131s\u0131 bak\u0131m\u0131ndan \u00f6nemli farkl\u0131l\u0131klar bulunmaktad\u0131r. Bu nedenle \u201cPRP\u201d ad\u0131 alt\u0131nda uygulanan<\/p>\n\n\n\n<p class=\"gtfy-118 wp-block-paragraph\">b\u00fct\u00fcn \u00fcr\u00fcnlerin biyolojik olarak ayn\u0131 oldu\u011funu d\u00fc\u015f\u00fcnmek do\u011fru de\u011fildir. 2026 y\u0131l\u0131nda yay\u0131mlanan ve 56 randomize \u00e7al\u0131\u015fmay\u0131 i\u00e7eren bir a\u011f meta-analizi de trombosit veya l\u00f6kosit yo\u011funlu\u011funu daha fazla art\u0131rman\u0131n her zaman daha iyi klinik sonu\u00e7 sa\u011flamad\u0131\u011f\u0131n\u0131 g\u00f6sterdi. \u0130deal PRP bile\u015fimi, dozu ve uygulama protokol\u00fc halen tam olarak belirlenmi\u015f de\u011fildir.<\/p>\n\n\n\n<p class=\"gtfy-121 wp-block-paragraph\"><strong>MR \u00e7al\u0131\u015fmalar\u0131nda k\u0131k\u0131rdak art\u0131\u015f\u0131 g\u00f6sterildi mi?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-124 wp-block-paragraph\">PRP\u2019nin k\u0131k\u0131rdak \u00fczerindeki etkisini de\u011ferlendirmek amac\u0131yla \u00e7e\u015fitli MR \u00e7al\u0131\u015fmalar\u0131 yap\u0131lm\u0131\u015ft\u0131r. Ancak bu ara\u015ft\u0131rmalar\u0131n sonu\u00e7lar\u0131 birbiriyle tamamen uyumlu de\u011fildir.<\/p>\n\n\n\n<p class=\"gtfy-127 wp-block-paragraph\"><strong>B\u00fcy\u00fck plasebo kontroll\u00fc \u00e7al\u0131\u015fma ne g\u00f6sterdi?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-130 wp-block-paragraph\">JAMA\u2019da yay\u0131mlanan RESTORE \u00e7al\u0131\u015fmas\u0131nda, hafif ve orta dereceli diz osteoartriti bulunan 288 hasta incelendi. Hastalara \u00fc\u00e7 hafta arayla l\u00f6kositten fakir PRP veya salin enjeksiyonu uyguland\u0131.<\/p>\n\n\n\n<p class=\"gtfy-133 wp-block-paragraph\"><strong>On iki ay sonunda:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-136 wp-block-paragraph\">PRP ile salin aras\u0131nda a\u011fr\u0131 azalmas\u0131 bak\u0131m\u0131ndan anlaml\u0131 fark bulunmad\u0131.<\/p>\n\n\n\n<p class=\"gtfy-139 wp-block-paragraph\">Medial tibial k\u0131k\u0131rdak hacmi kayb\u0131 bak\u0131m\u0131ndan anlaml\u0131 fark saptanmad\u0131.<\/p>\n\n\n\n<p class=\"gtfy-142 wp-block-paragraph\">PRP\u2019nin hastal\u0131\u011f\u0131n yap\u0131sal ilerlemesini yava\u015flatt\u0131\u011f\u0131 g\u00f6sterilemedi.<\/p>\n\n\n\n<p class=\"gtfy-145 wp-block-paragraph\">PRP grubunda medial tibial k\u0131k\u0131rdak hacmi yakla\u015f\u0131k %1,4, salin grubunda ise %1,2 oran\u0131nda azald\u0131.<\/p>\n\n\n\n<p class=\"gtfy-148 wp-block-paragraph\">Bu \u00e7al\u0131\u015fma, PRP\u2019nin k\u0131k\u0131rda\u011f\u0131 korudu\u011fu veya yeniden olu\u015fturdu\u011fu iddias\u0131n\u0131 desteklemeyen en g\u00fc\u00e7l\u00fc randomize ara\u015ft\u0131rmalardan biridir.<\/p>\n\n\n\n<p class=\"gtfy-151 wp-block-paragraph\"><strong>K\u0131k\u0131rdak kalitesinde de\u011fi\u015fiklik olabilir mi?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-154 wp-block-paragraph\">2024 y\u0131l\u0131nda yay\u0131mlanan randomize bir MR \u00e7al\u0131\u015fmas\u0131nda PRP; hyal\u00fcronik asit, glukokortikoid ve plasebo ile<\/p>\n\n\n\n<p class=\"gtfy-157 wp-block-paragraph\">kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131. Ara\u015ft\u0131rmada standart morfolojik MR \u00f6l\u00e7\u00fcmlerinde belirgin k\u0131k\u0131rdak art\u0131\u015f\u0131 g\u00f6r\u00fclmedi.<\/p>\n\n\n\n<p class=\"gtfy-160 wp-block-paragraph\">Bununla birlikte PRP grubunda baz\u0131 diz b\u00f6lgelerinde T2 haritalama de\u011ferlerinde olumlu de\u011fi\u015fiklikler saptand\u0131. T2 haritalama, k\u0131k\u0131rdak i\u00e7erisindeki su i\u00e7eri\u011fi ve kollajen organizasyonu hakk\u0131nda dolayl\u0131 bilgi verebilir.<\/p>\n\n\n\n<p class=\"gtfy-163 wp-block-paragraph\">Bu t\u00fcr de\u011fi\u015fiklikler k\u0131k\u0131rdak matriksinin biyolojik \u00f6zelliklerinde iyile\u015fme olabilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrebilir. Ancak<\/p>\n\n\n\n<p class=\"gtfy-166 wp-block-paragraph\">MR sinyalindeki bir de\u011fi\u015fiklik, yeni ve normal k\u0131k\u0131rdak olu\u015ftu\u011funun do\u011frudan kan\u0131t\u0131 de\u011fildir.<\/p>\n\n\n\n<p class=\"gtfy-169 wp-block-paragraph\"><strong>Olumlu yap\u0131sal sonu\u00e7 bildiren \u00e7al\u0131\u015fmalar var m\u0131?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-172 wp-block-paragraph\">Evet. Baz\u0131 k\u00fc\u00e7\u00fck \u00e7al\u0131\u015fmalar PRP sonras\u0131nda belirli diz kompart\u0131manlar\u0131nda k\u0131k\u0131rdak kal\u0131nl\u0131\u011f\u0131 art\u0131\u015f\u0131 bildirmi\u015ftir.<\/p>\n\n\n\n<p class=\"gtfy-175 wp-block-paragraph\">2025 y\u0131l\u0131nda yay\u0131mlanan 63 hastal\u0131k randomize bir \u00e7al\u0131\u015fmada, PRP uygulanan gruplarda baz\u0131 medial tibial ve patellar k\u0131k\u0131rdak kal\u0131nl\u0131\u011f\u0131 \u00f6l\u00e7\u00fcmlerinin salin grubuna g\u00f6re daha iyi oldu\u011fu bildirildi.<\/p>\n\n\n\n<p class=\"gtfy-178 wp-block-paragraph\"><strong>Ancak bu sonu\u00e7lar\u0131n:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-181 wp-block-paragraph\">K\u00fc\u00e7\u00fck bir hasta grubundan elde edilmesi,<\/p>\n\n\n\n<p class=\"gtfy-184 wp-block-paragraph\">Takip s\u00fcresinin alt\u0131 ay olmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-187 wp-block-paragraph\">Sadece belirli k\u0131k\u0131rdak b\u00f6lgelerinde de\u011fi\u015fiklik g\u00f6sterilmesi,<\/p>\n\n\n\n<p class=\"gtfy-190 wp-block-paragraph\">Di\u011fer b\u00fcy\u00fck \u00e7al\u0131\u015fmalarla tam olarak do\u011frulanmam\u0131\u015f olmas\u0131 nedeniyle temkinli yorumlanmas\u0131 gerekir.<\/p>\n\n\n\n<p class=\"gtfy-193 wp-block-paragraph\">Bir ba\u015fka 2025 \u00e7al\u0131\u015fmas\u0131nda \u00fc\u00e7 boyutlu MR ile 21 diz de\u011ferlendirildi. Osteoartritten en fazla etkilenen \u00a0posteromedial femur ve medial tibia b\u00f6lgelerinde belirgin kal\u0131nl\u0131k art\u0131\u015f\u0131 hastalar\u0131n %20\u2019sinden az\u0131nda g\u00f6r\u00fcld\u00fc. K\u0131k\u0131rdak kal\u0131nl\u0131\u011f\u0131 de\u011fi\u015fikli\u011fi ile hastalar\u0131n klinik skorlar\u0131 aras\u0131nda da anlaml\u0131 bir ili\u015fki bulunmad\u0131.<\/p>\n\n\n\n<p class=\"gtfy-196 wp-block-paragraph\">Sonu\u00e7 olarak MR \u00e7al\u0131\u015fmalar\u0131nda baz\u0131 olumlu biyolojik veya yap\u0131sal sinyaller bulunsa da, bu veriler hen\u00fcz PRP\u2019nin kaybedilmi\u015f k\u0131k\u0131rda\u011f\u0131 g\u00fcvenilir bi\u00e7imde yeniden olu\u015fturdu\u011funu s\u00f6ylemek i\u00e7in yeterli de\u011fildir.<\/p>\n\n\n\n<p class=\"gtfy-199 wp-block-paragraph\"><strong>PRP \u00e7al\u0131\u015fmalar\u0131n\u0131n sonu\u00e7lar\u0131 neden birbirinden farkl\u0131?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-202 wp-block-paragraph\"><strong>PRP tek bir ila\u00e7 veya tek bir standart \u00fcr\u00fcn de\u011fildir.<\/strong> Uygulanan \u00fcr\u00fcn\u00fcn \u00f6zellikleri \u015fu fakt\u00f6rlere g\u00f6re <strong>de\u011fi\u015febilir:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-205 wp-block-paragraph\">Hastadan al\u0131nan kan miktar\u0131,<\/p>\n\n\n\n<p class=\"gtfy-208 wp-block-paragraph\">Kullan\u0131lan haz\u0131rlama sistemi,<\/p>\n\n\n\n<p class=\"gtfy-211 wp-block-paragraph\">Santrif\u00fcj h\u0131z\u0131 ve s\u00fcresi,<\/p>\n\n\n\n<p class=\"gtfy-214 wp-block-paragraph\">Trombosit yo\u011funlu\u011fu,<\/p>\n\n\n\n<p class=\"gtfy-217 wp-block-paragraph\">L\u00f6kositlerin \u00fcr\u00fcnde bulunup bulunmamas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-220 wp-block-paragraph\">Eritrosit kontaminasyonu,<\/p>\n\n\n\n<p class=\"gtfy-223 wp-block-paragraph\">PRP\u2019nin aktive edilip edilmemesi,<\/p>\n\n\n\n<p class=\"gtfy-226 wp-block-paragraph\">Enjeksiyon say\u0131s\u0131 ve enjeksiyonlar aras\u0131ndaki s\u00fcre,<\/p>\n\n\n\n<p class=\"gtfy-229 wp-block-paragraph\">Uygulaman\u0131n ultrason e\u015fli\u011finde yap\u0131l\u0131p yap\u0131lmamas\u0131.<\/p>\n\n\n\n<p class=\"gtfy-232 wp-block-paragraph\"><strong>Hasta kaynakl\u0131 fakt\u00f6rler de sonucu etkileyebilir:<\/strong>\u00a0 \u00a0 \u00a0\u00a0<\/p>\n\n\n\n<p class=\"gtfy-235 wp-block-paragraph\">Osteoartritin evresi,<\/p>\n\n\n\n<p class=\"gtfy-238 wp-block-paragraph\">Ya\u015f,<\/p>\n\n\n\n<p class=\"gtfy-241 wp-block-paragraph\">V\u00fccut a\u011f\u0131rl\u0131\u011f\u0131,<\/p>\n\n\n\n<p class=\"gtfy-244 wp-block-paragraph\">Dizilim bozuklu\u011fu,<\/p>\n\n\n\n<p class=\"gtfy-247 wp-block-paragraph\">Menisk\u00fcs hasar\u0131,<\/p>\n\n\n\n<p class=\"gtfy-250 wp-block-paragraph\">Sinovit varl\u0131\u011f\u0131,<\/p>\n\n\n\n<p class=\"gtfy-253 wp-block-paragraph\">Kas g\u00fcc\u00fc,<\/p>\n\n\n\n<p class=\"gtfy-256 wp-block-paragraph\">G\u00fcnl\u00fck fiziksel y\u00fcklenme,<\/p>\n\n\n\n<p class=\"gtfy-259 wp-block-paragraph\">Metabolik ve inflamatuvar hastal\u0131klar.<\/p>\n\n\n\n<p class=\"gtfy-262 wp-block-paragraph\">Bu heterojenlik, bir \u00e7al\u0131\u015fmada olumlu bulunan protokol\u00fcn ba\u015fka bir \u00e7al\u0131\u015fmada ayn\u0131 sonucu vermemesinin<\/p>\n\n\n\n<p class=\"gtfy-265 wp-block-paragraph\">temel nedenlerinden biridir.<\/p>\n\n\n\n<p class=\"gtfy-268 wp-block-paragraph\">4PRP kimlerde daha fazla d\u00fc\u015f\u00fcn\u00fclebilir?<\/p>\n\n\n\n<p class=\"gtfy-271 wp-block-paragraph\">Uluslararas\u0131 uzman uzla\u015f\u0131lar\u0131, PRP\u2019nin \u00f6zellikle hafif ve orta dereceli diz osteoartriti, yani \u00e7o\u011funlukla<\/p>\n\n\n\n<p class=\"gtfy-274 wp-block-paragraph\">Kellgren\u2013Lawrence evre 1\u20133 hastalarda de\u011ferlendirilebilece\u011fini belirtmektedir.<\/p>\n\n\n\n<p class=\"gtfy-277 wp-block-paragraph\"><strong>PRP \u015fu durumlarda tedavi se\u00e7eneklerinden biri olarak ele al\u0131nabilir:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-280 wp-block-paragraph\">Egzersiz ve ya\u015fam tarz\u0131 d\u00fczenlemelerine ra\u011fmen devam eden diz a\u011fr\u0131s\u0131,<\/p>\n\n\n\n<p class=\"gtfy-283 wp-block-paragraph\">Hafif veya orta dereceli osteoartrit,<\/p>\n\n\n\n<p class=\"gtfy-286 wp-block-paragraph\">Hastan\u0131n semptomlar\u0131n\u0131n g\u00fcnl\u00fck ya\u015fam\u0131n\u0131 belirgin etkilemesi,<\/p>\n\n\n\n<p class=\"gtfy-289 wp-block-paragraph\">Tedavi hedefinin ger\u00e7ek\u00e7i bi\u00e7imde a\u011fr\u0131 ve fonksiyon \u00fczerine kurulmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-292 wp-block-paragraph\">Uygulama sonras\u0131nda uygun rehabilitasyon program\u0131n\u0131n planlanmas\u0131.<\/p>\n\n\n\n<p class=\"gtfy-295 wp-block-paragraph\">\u0130leri derecede eklem aral\u0131\u011f\u0131 kayb\u0131, ciddi varus veya valgus deformitesi ve belirgin mekanik bozukluk bulunan hastalarda PRP\u2019nin sonucu daha az \u00f6ng\u00f6r\u00fclebilir olabilir. PRP\u2019nin ileri osteoartritte kaybedilmi\u015f eklem y\u00fczeyini yeniden olu\u015fturdu\u011fu veya protez gereksinimini kesin bi\u00e7imde ortadan kald\u0131rd\u0131\u011f\u0131 s\u00f6ylenemez.<\/p>\n\n\n\n<p class=\"gtfy-298 wp-block-paragraph\"><strong>PRP egzersiz ve rehabilitasyonun yerine ge\u00e7er mi?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-301 wp-block-paragraph\">Hay\u0131r. PRP, diz osteoartritinin temel tedavilerinin yerine ge\u00e7en tek ba\u015f\u0131na bir \u00e7\u00f6z\u00fcm olarak g\u00f6r\u00fclmemelidir.<\/p>\n\n\n\n<p class=\"gtfy-304 wp-block-paragraph\"><strong>Diz osteoartritinde tedavinin temel bile\u015fenleri \u015funlard\u0131r:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-307 wp-block-paragraph\">Hastaya \u00f6zel egzersiz program\u0131,<\/p>\n\n\n\n<p class=\"gtfy-310 wp-block-paragraph\">Kuadriseps ve kal\u00e7a \u00e7evresi kaslar\u0131n\u0131n g\u00fc\u00e7lendirilmesi,<\/p>\n\n\n\n<p class=\"gtfy-313 wp-block-paragraph\">Eklem hareket a\u00e7\u0131kl\u0131\u011f\u0131n\u0131n korunmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-316 wp-block-paragraph\">V\u00fccut a\u011f\u0131rl\u0131\u011f\u0131n\u0131n y\u00f6netilmesi,<\/p>\n\n\n\n<p class=\"gtfy-319 wp-block-paragraph\">Y\u00fcr\u00fcme ve hareket paternlerinin d\u00fczenlenmesi,<\/p>\n\n\n\n<p class=\"gtfy-322 wp-block-paragraph\">Gerekti\u011finde ortez veya yard\u0131mc\u0131 cihaz kullan\u0131lmas\u0131,<\/p>\n\n\n\n<p class=\"gtfy-325 wp-block-paragraph\">Aktivite y\u00fck\u00fcn\u00fcn do\u011fru dozlanmas\u0131.<\/p>\n\n\n\n<p class=\"gtfy-328 wp-block-paragraph\">Uluslararas\u0131 osteoartrit \u00f6nerileri de e\u011fitim, egzersiz ve gerekli hastalarda kilo y\u00f6netimini tedavinin temel bile\u015fenleri aras\u0131nda kabul etmektedir.<\/p>\n\n\n\n<p class=\"gtfy-331 wp-block-paragraph\">Biyolojik bir enjeksiyon yap\u0131ld\u0131ktan sonra dokunun maruz kalaca\u011f\u0131 mekanik \u00e7evrenin d\u00fczenlenmemesi, kas zay\u0131fl\u0131\u011f\u0131n\u0131n devam etmesi ve hatal\u0131 y\u00fcklenmenin s\u00fcrmesi tedavinin potansiyel etkisini s\u0131n\u0131rlayabilir.<\/p>\n\n\n\n<p class=\"gtfy-334 wp-block-paragraph\">Bu nedenle g\u00fcncel yakla\u015f\u0131m yaln\u0131zca \u201cekleme ne enjekte edildi\u011fine\u201d de\u011fil, enjeksiyon sonras\u0131nda eklemin nas\u0131l y\u00fcklendi\u011fine ve hastan\u0131n nas\u0131l rehabilite edildi\u011fine de odaklanmal\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"gtfy-337 wp-block-paragraph\"><strong>PRP tedavisinden \u00f6nce hangi sorular sorulmal\u0131d\u0131r?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-340 wp-block-paragraph\"><strong>PRP yapt\u0131rmay\u0131 d\u00fc\u015f\u00fcnen bir hasta, hekimine \u015fu sorular\u0131 y\u00f6neltebilir:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-343 wp-block-paragraph\">1.\u00a0Diz a\u011fr\u0131m\u0131n temel nedeni ger\u00e7ekten osteoartrit mi?<\/p>\n\n\n\n<p class=\"gtfy-346 wp-block-paragraph\">2.\u00a0Osteoartritimin radyolojik ve klinik evresi nedir?<\/p>\n\n\n\n<p class=\"gtfy-349 wp-block-paragraph\">3. Benim i\u00e7in PRP\u2019den beklenen hedef a\u011fr\u0131 azalmas\u0131 m\u0131, fonksiyon art\u0131\u015f\u0131 m\u0131?<\/p>\n\n\n\n<p class=\"gtfy-352 wp-block-paragraph\">4. Kullan\u0131lacak PRP\u2019nin trombosit ve l\u00f6kosit \u00f6zellikleri biliniyor mu?<\/p>\n\n\n\n<p class=\"gtfy-355 wp-block-paragraph\">5. Ka\u00e7 enjeksiyon planlan\u0131yor ve bu protokol hangi kan\u0131ta dayan\u0131yor?<\/p>\n\n\n\n<p class=\"gtfy-358 wp-block-paragraph\">6. Uygulama ultrason e\u015fli\u011finde mi yap\u0131lacak?<\/p>\n\n\n\n<p class=\"gtfy-361 wp-block-paragraph\">7. PRP sonras\u0131nda rehabilitasyon ve y\u00fcklenme program\u0131m nas\u0131l olacak?<\/p>\n\n\n\n<p class=\"gtfy-364 wp-block-paragraph\">8. Alternatif tedavi se\u00e7eneklerim nelerdir?<\/p>\n\n\n\n<p class=\"gtfy-367 wp-block-paragraph\">Hastaya \u201cPRP k\u0131k\u0131rda\u011f\u0131n\u0131z\u0131 kesin olarak yenileyecek\u201d veya \u201cdiz protezine hi\u00e7bir zaman ihtiya\u00e7 duymayacaks\u0131n\u0131z\u201d \u015feklinde garanti verilmesi mevcut bilimsel kan\u0131tlarla uyumlu de\u011fildir.<\/p>\n\n\n\n<p class=\"gtfy-370 wp-block-paragraph\"><strong>Sonu\u00e7: PRP\u2019den ne beklemeliyiz?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-373 wp-block-paragraph\">PRP, diz osteoartritinde baz\u0131 hastalarda a\u011fr\u0131y\u0131 azaltabilecek ve fonksiyonu iyile\u015ftirebilecek biyolojik bir tedavi se\u00e7ene\u011fidir. \u00d6zellikle hafif ve orta dereceli osteoartritte, do\u011fru hasta se\u00e7imi ve uygun rehabilitasyonla klinik yarar sa\u011flanabilir.<\/p>\n\n\n\n<p class=\"gtfy-376 wp-block-paragraph\"><strong>Bununla birlikte g\u00fcncel bilimsel kan\u0131tlar PRP\u2019nin:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-379 wp-block-paragraph\">Kaybedilmi\u015f k\u0131k\u0131rda\u011f\u0131 d\u00fczenli bi\u00e7imde yeniden olu\u015fturdu\u011funu,<\/p>\n\n\n\n<p class=\"gtfy-382 wp-block-paragraph\">Eklem y\u00fczeyini normal hiyalin k\u0131k\u0131rdakla kaplad\u0131\u011f\u0131n\u0131,<\/p>\n\n\n\n<p class=\"gtfy-385 wp-block-paragraph\">Osteoartritin ilerlemesini kesin olarak durdurdu\u011funu, Cerrahi gereksinimini ortadan kald\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6stermemektedir.<\/p>\n\n\n\n<p class=\"gtfy-388 wp-block-paragraph\"><strong>Dolay\u0131s\u0131yla en do\u011fru ifade \u015fudur:<\/strong><\/p>\n\n\n\n<p class=\"gtfy-391 wp-block-paragraph\">PRP, k\u0131k\u0131rdak ve eklem \u00e7evresindeki biyolojik ortam\u0131 etkileyebilir ve baz\u0131 hastalarda klinik iyile\u015fme sa\u011flayabilir; ancak bug\u00fcn i\u00e7in PRP\u2019ye \u201ckan\u0131tlanm\u0131\u015f k\u0131k\u0131rdak yenileyici tedavi\u201d demek bilimsel olarak do\u011fru de\u011fildir.<\/p>\n\n\n\n<p class=\"gtfy-394 wp-block-paragraph\">Tedavi karar\u0131; hastan\u0131n ya\u015f\u0131, osteoartrit evresi, dizilimi, kas g\u00fcc\u00fc, e\u015flik eden hastal\u0131klar\u0131, aktivite d\u00fczeyi ve beklentileri birlikte de\u011ferlendirilerek verilmelidir.<\/p>\n\n\n\n<p class=\"gtfy-397 wp-block-paragraph\"><strong>Frequently Asked Questions<\/strong><\/p>\n\n\n\n<p class=\"gtfy-400 wp-block-paragraph\"><strong>PRP sonras\u0131nda a\u011fr\u0131m azald\u0131ysa k\u0131k\u0131rda\u011f\u0131m yenilenmi\u015f midir?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-403 wp-block-paragraph\">Hay\u0131r. A\u011fr\u0131 azalmas\u0131; inflamasyonun d\u00fczenlenmesi, sinovyal \u00e7evrenin de\u011fi\u015fmesi veya a\u011fr\u0131yla ili\u015fkili biyolojik mekanizmalar\u0131n etkilenmesi sonucunda ortaya \u00e7\u0131kabilir. K\u0131k\u0131rdak yenilenmesini g\u00f6stermek i\u00e7in objektif ve uzun d\u00f6nemli yap\u0131sal de\u011ferlendirme gerekir.<\/p>\n\n\n\n<p class=\"gtfy-406 wp-block-paragraph\"><strong>MR\u2019da k\u0131k\u0131rdak kal\u0131nl\u0131\u011f\u0131n\u0131n artmas\u0131 kesin rejenerasyon anlam\u0131na gelir mi?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-409 wp-block-paragraph\">Tek bir MR \u00f6l\u00e7\u00fcm\u00fcndeki k\u00fc\u00e7\u00fck kal\u0131nl\u0131k art\u0131\u015f\u0131 tek ba\u015f\u0131na kesin rejenerasyon kan\u0131t\u0131 de\u011fildir. \u00d6l\u00e7\u00fcm y\u00f6ntemi, k\u0131k\u0131rdak hidrasyonu, analiz tekni\u011fi ve de\u011fi\u015fikli\u011fin hangi b\u00f6lgede meydana geldi\u011fi dikkate al\u0131nmal\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"gtfy-412 wp-block-paragraph\"><strong>PRP osteoartritin ilerlemesini durdurur mu?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-415 wp-block-paragraph\">PRP\u2019nin osteoartritin yap\u0131sal ilerlemesini kesin olarak durdurdu\u011fu kan\u0131tlanmam\u0131\u015ft\u0131r. B\u00fcy\u00fck plasebo kontroll\u00fc \u00e7al\u0131\u015fmalarda k\u0131k\u0131rdak hacim kayb\u0131n\u0131n \u00f6nlendi\u011fi g\u00f6sterilememi\u015ftir.<\/p>\n\n\n\n<p class=\"gtfy-418 wp-block-paragraph\"><strong>Ka\u00e7 seans PRP yap\u0131lmal\u0131d\u0131r?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-421 wp-block-paragraph\">Herkes i\u00e7in kabul edilmi\u015f tek bir enjeksiyon say\u0131s\u0131 bulunmamaktad\u0131r. Ara\u015ft\u0131rmalarda tek enjeksiyondan \u00fc\u00e7 veya daha fazla enjeksiyona kadar farkl\u0131 protokoller kullan\u0131lm\u0131\u015ft\u0131r. Tedavi say\u0131s\u0131 hastan\u0131n klinik durumuna, kullan\u0131lan \u00fcr\u00fcne ve hekimin de\u011ferlendirmesine g\u00f6re belirlenmelidir.<\/p>\n\n\n\n<p class=\"gtfy-424 wp-block-paragraph\"><strong>PRP k\u00f6k h\u00fccre tedavisi midir?<\/strong><\/p>\n\n\n\n<p class=\"gtfy-427 wp-block-paragraph\">Hay\u0131r. PRP hastan\u0131n kan\u0131ndan haz\u0131rlanan, trombosit ve plazma i\u00e7eren bir \u00fcr\u00fcnd\u00fcr. K\u00f6k h\u00fccre tedavisiyle ayn\u0131 de\u011fildir.<\/p>\n\n\n\n<p class=\"gtfy-430 wp-block-paragraph\"><strong>Kaynaklar<\/strong><\/p>\n\n\n\n<p class=\"gtfy-433 wp-block-paragraph\">Bennell, K. L., Paterson, K. L., Metcalf, B. R., et al. (2021). Effect of intra-articular platelet-rich plasma<\/p>\n\n\n\n<p class=\"gtfy-436 wp-block-paragraph\">vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis:<\/p>\n\n\n\n<p class=\"gtfy-439 wp-block-paragraph\">The RESTORE randomized clinical trial. JAMA, 326(20), 2021\u20132030. doi:10.1001\/jama.2021.19415.<\/p>\n\n\n\n<p class=\"gtfy-442 wp-block-paragraph\">Bensa, A., et al. (2025). Efficacy of platelet-rich plasma versus placebo in knee osteoarthritis: A<\/p>\n\n\n\n<p class=\"gtfy-445 wp-block-paragraph\">systematic review and meta-analysis of randomized controlled trials. American Journal of Sports<\/p>\n\n\n\n<p class=\"gtfy-448 wp-block-paragraph\">Medicine, 53(3), 745\u2013754.<\/p>\n\n\n\n<p class=\"gtfy-451 wp-block-paragraph\">Tschopp, M., et al. (2024). Quantitative and morphological MRI assessment after intra-articular<\/p>\n\n\n\n<p class=\"gtfy-454 wp-block-paragraph\">treatment of knee osteoarthritis: A randomized placebo-controlled study. Investigative Radiology,<\/p>\n\n\n\n<p class=\"gtfy-457 wp-block-paragraph\">59(9), 646\u2013655.<\/p>\n\n\n\n<p class=\"gtfy-460 wp-block-paragraph\">Ghadamzadeh, M., et al. (2025). Clinical and MRI outcomes of single- and double-centrifuged<\/p>\n\n\n\n<p class=\"gtfy-463 wp-block-paragraph\">platelet-rich plasma in knee osteoarthritis: A randomized controlled trial. Archives of Bone and Joint Surgery, 13(9), 572\u2013581.<\/p>\n\n\n\n<p class=\"gtfy-466 wp-block-paragraph\">Sekiya, I., et al. (2025). Three-dimensional MRI analysis of articular cartilage after platelet-rich plasma<\/p>\n\n\n\n<p class=\"gtfy-469 wp-block-paragraph\">treatment for knee osteoarthritis: A preliminary report. PLOS ONE, 20(4), e0321067.<\/p>\n\n\n\n<p class=\"gtfy-472 wp-block-paragraph\">Anitua, E., et al. (2026). Platelet-rich plasma composition and clinical outcomes in knee osteoarthritis:<\/p>\n\n\n\n<p class=\"gtfy-475 wp-block-paragraph\">A systematic review and network meta-analysis. Knee Surgery &amp; Related Research, 38, 17. doi:10.1186\/s43019-026-00318-4.<\/p>\n\n\n\n<p class=\"gtfy-478 wp-block-paragraph\">Laver, L., et al. (2024). ESSKA\u2013ICRS consensus on the use of injectable orthobiologics in knee<\/p>\n\n\n\n<p class=\"gtfy-481 wp-block-paragraph\">osteoarthritis. Knee Surgery, Sports Traumatology, Arthroscopy, 32, 783\u2013797.<\/p>\n\n\n\n<p class=\"gtfy-484 wp-block-paragraph\">Kon, E., et al. (2024). ESSKA\u2013ORBIT consensus: Use of platelet-rich plasma injections in knee<\/p>\n\n\n\n<p class=\"gtfy-487 wp-block-paragraph\">osteoarthritis. Knee Surgery, Sports Traumatology, Arthroscopy, 32, 2938\u20132949.<\/p>\n\n\n\n<p class=\"gtfy-490 wp-block-paragraph\">Bilgilendirme: Bu yaz\u0131 genel sa\u011fl\u0131k bilgisi sunmak amac\u0131yla haz\u0131rlanm\u0131\u015ft\u0131r. Bireysel tan\u0131 ve tedavi \u00f6nerisi yerine ge\u00e7mez.<\/p>","protected":false},"excerpt":{"rendered":"<p>PRP k\u0131k\u0131rda\u011f\u0131 ger\u00e7ekten yeniler mi? Diz kire\u00e7lenmesi nedeniyle PRP tedavisi d\u00fc\u015f\u00fcnen hastalar\u0131n en s\u0131k sordu\u011fu [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2399,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_gutenify_countdown_timer_type":"fixed","_gutenify_countdown_timer_evergreen_hours":24,"_gutenify_countdown_timer_evergreen_minutes":0,"_gutenify_countdown_timer_date":"","_gutenify_countdown_timer_timezone":"US\/Eastern","_gutenify_countdown_timer_end_action":"none","_gutenify_countdown_timer_hide_selector":"","_gutenify_countdown_timer_redirect_url":"","_joinchat":[],"footnotes":""},"categories":[],"tags":[],"class_list":["post-2398","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/posts\/2398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/comments?post=2398"}],"version-history":[{"count":2,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/posts\/2398\/revisions"}],"predecessor-version":[{"id":2401,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/posts\/2398\/revisions\/2401"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/media\/2399"}],"wp:attachment":[{"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/media?parent=2398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/categories?post=2398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/tags?post=2398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}